Clinical Trial

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-11-11 2026-07-03
minor Completion pushed: 2026-07-31 -> 2026-11-11 2026-07-03
Trial Details
NCT Number NCT07343960
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Moderate Hepatic Impairment
Enrollment 20 participants
Start Date 2026-01-06
Primary Completion 2026-11-11 (estimated)
Study Completion 2026-11-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-02